Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, United Therapeutics's Enterprise Value is €17,659 Mil.
United Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €1,396 Mil. Therefore, United Therapeutics's EV-to-EBIT ratio for today is 12.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, United Therapeutics's Enterprise Value is €17,659 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €1,472 Mil. Therefore, United Therapeutics's EV-to-EBITDA ratio for today is 12.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, United Therapeutics's Enterprise Value is €17,659 Mil.
United Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €2,724 Mil. Therefore, United Therapeutics's EV-to-Revenue ratio for today is 6.48.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
United Therapeutics (FRA:UTH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
United Therapeutics's current Enterprise Value is €17,659 Mil.
United Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,396 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
United Therapeutics's current Enterprise Value is €17,659 Mil.
United Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,472 Mil.
United Therapeutics's current Enterprise Value is €17,659 Mil.
United Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,724 Mil.
United Therapeutics's current Enterprise Value is €17,659 Mil.
United Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,342 Mil.
United Therapeutics's current Enterprise Value is €17,659 Mil.
United Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €869 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Enterprise Value Related Terms
United Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
United Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a Enterprise Value of €17,659 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Enterprise Value too high?
United Therapeutics' current Enterprise Value is €17,659 Mil. Overall, United Therapeutics has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Enterprise Value compare to VTRS and NBIX?
United Therapeutics' Enterprise Value of €17,659 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on United Therapeutics and its competitors. United Therapeutics's current Enterprise Value is €17,659 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €332.97, compared to a current price of €471.60 — trading 41.6% above its estimated fair value. The current Enterprise Value is €17,659 Mil. United Therapeutics' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current Enterprise Value is €17,659 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €471.60 is trading 41.6% above its estimated GF Value™ of €332.97.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
Enterprise Value: €17,659 Mil
GF Value™: €332.97 vs. price of €471.60 (41.6% above fair value)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
83GF Score
Get the complete analysis for FRA:UTH
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
